BiotechTube

Topical Beremagene Geperpavec

Phase 3Completed
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dystrophic Epidermolysis Bullosa

Conditions

Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa

Trial Timeline

Aug 17, 2020 → Jan 14, 2022

NCT ID
NCT04491604

About Topical Beremagene Geperpavec

Topical Beremagene Geperpavec is a phase 3 stage product being developed by Krystal Biotech for Dystrophic Epidermolysis Bullosa. The current trial status is completed. This product is registered under clinical trial identifier NCT04491604. Target conditions include Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04491604Phase 3Completed

Competing Products

4 competing products in Dystrophic Epidermolysis Bullosa

See all competitors
ProductCompanyStageHype Score
KB803 + PlaceboKrystal BiotechPhase 3
74
Topical beremagene geperpavec + Placebo gelKrystal BiotechPhase 1/2
38
Open Label Topical Beremagene Geperpavec (B-VEC)Krystal BiotechPhase 3
74
LZRSE-Col7A1 Engineered Autologous Epidermal SheetsAbeona TherapeuticsPhase 1/2
33

Other Products from Krystal Biotech

KB803 + PlaceboPhase 3
74
Open Label Topical Beremagene Geperpavec (B-VEC)Phase 3
74
KB105Phase 2
49
Topical beremagene geperpavec + Placebo gelPhase 1/2
38
KB707 + Opdualag + KEYTRUDA ®( Pembrolizumab)Phase 1/2
38